1-3 of 3
Karl Ziegelbauer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers

Urs B. Hagemann, Christine Ellingsen, Joachim Schuhmacher, Alexander Kristian, Anne Mobergslien, Véronique Cruciani, Katrine Wickstroem, Christoph A. Schatz, Christoph Kneip, Sven Golfier, Roger Smeets, Steinar Uran, Hartwig Hennekes, Jenny Karlsson, Roger M. Bjerke, Olav B. Ryan, Dominik Mumberg, Karl Ziegelbauer, Alan S. Cuthbertson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (15): 4723–4734.
https://doi.org/10.1158/1078-0432.CCR-18-3476
Published: 01 August 2019
View article titled, Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers
Open the PDF for Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers in another window
Includes: Supplementary data
Journal Articles

Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández-Montalván, Wilhelm Bone, Jens Schröder, Sabine Zitzmann-Kolbe, Hans Briem, Stefan Prechtl, Simon J. Holton, Ursula Mönning, Oliver von Ahsen, Sandra Johanssen, Arwed Cleve, Vera Pütter, Marion Hitchcock, Franz von Nussbaum, Michael Brands, Karl Ziegelbauer, Dominik Mumberg
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1404–1414.
https://doi.org/10.1158/1078-0432.CCR-18-0628
Published: 15 February 2019
View article titled, Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models

Mari I. Suominen, Katja M. Fagerlund, Jukka P. Rissanen, Yvonne M. Konkol, Jukka P. Morko, ZhiQi Peng, Esa J. Alhoniemi, Salla K. Laine, Eva Corey, Dominik Mumberg, Karl Ziegelbauer, Sanna-Maria Käkönen, Jussi M. Halleen, Robert L. Vessella, Arne Scholz
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (15): 4335–4346.
https://doi.org/10.1158/1078-0432.CCR-16-2955
Published: 01 August 2017
View article titled, Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models
Open the PDF for Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models in another window
Includes: Supplementary data